MARCH - APRIL 2022LIFE SCIENCES REVIEW6The last 12 months were full of challenges for trial sponsors and the clinical trials market saw dynamic change when the pandemic introduced new logistical problems that had to be confronted and solved rapidly. Now, as the dust begins to settle, pharmaceutical companies are faced with a market that looks quite different to the one before, while trends they were already familiar with continue to grow.While Decentralized Clinical Trials have existed before, the advent of the pandemic has propelled them to industry-shaping-trend status. And though many of the pandemic restrictions which initially accelerated the trending rise of DCTs are now relaxing, the progress made in improving the applicability of Decentralized Clinical Trials promises the continued rise of the trend, despite a possible reduction in the degree of the trend's rise in the immediate future.Another reason for the reduction of the rise in this trend's degree in the immediate future is conservative backpedaling, which may have some industry leaders increasing their reliance on methods they are more familiar with, even when the investigations in question are not necessarily more suited to conventional clinical trials. Still, DCTs remain a strong upcoming trend in the clinical trial industry and are here to stay. Having majorly come to the forefront during the pandemic and with an expectation of minorly receding from the scene in the immediate aftermath, the DCT trend is expected to sustainably grow in the foreseeable future, having demonstrated considerable progress in applicability during the pandemic.An additional factor that caused this trend to precede the COVID-19 crisis and grow throughout it relates to trial participants. eConsent is also beneficial for patients and trial participants in that it allows them to read the terms which inform their consent at their convenience before signing from any location where they have secure internet access. Depending on the eConsent solution used, participants may also be able to access all their electronically signed forms and the documents relating to them more easily. Let us know your thoughts.EDITORIALThe New Shape of Clinical Trials in 2022Copyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com March - April - 2022, Vol 03, Issue - 04 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comVictor Cruz
< Page 5 | Page 7 >